An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: Treatment rationale and protocol dynamics of the TORCH trial

Clinical Lung Cancer

Volumn 9, Issue 4, 2008, Pages 235-238

  Gridelli, Cesare ^a   Butts, Charles ^b   Ciardiello, Fortunato ^c   Feld, Ronald ^d   Gallo, Ciro ^c   Perrone, Francesco ^e  

^a S G MOSCATI HOSPITAL   (Italy)

^b CROSS CANCER INSTITUTE   (Canada)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Epidermal growth factor receptor; Pyrimidine analogue; Targeted therapy; Tyrosine kinase inhibitor

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEMCITABINE; K RAS PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 49249136311     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2008.n.037     Document Type: Article

References (20)

1. American Cancer Society. Cancer Facts & Figures 2006. Atlanta, GA: American Cancer Society, 2006. Available at: http://www.cancer.org. Accessed: May 12, 2007.
2. Coleman MP, Gatta G, Verdecchia A, et al. EUROCARE-3 summary: cancer survival in Europe at the end of 20th century. Ann Oncol 2003; 14 (suppl 5): 128-49.
3. Gridelli C, Gallo C, Shepherd F, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non small cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trial Group. J Clin Oncol 2003; 21:3025-34.
4. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. New Engl J Med 2002; 346:92-8.
5. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non small cell lung cancer. The MILES (Multicenter Italian Lung cancer in the Elderly Study) phase 3 randomized trial. J Natl Cancer Inst 2003; 95:362-72.
6. Le Chevalier T, Scagliotti G, Natale R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005; 47:69-80.
7. Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999; 17:12-8.
8. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cis-platin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18:122-30.
9. Gridelli C, Rossi A, Maione P. Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Oncogene 2003; 22:6629-38.
10. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25:1545-52.
11. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplarin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:5892-9.
12. Shepherd FA, Perira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-32.
13. Giaccone G, Ruiz Gallegos M, Le Chevalier T, et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 2006; 12:6049-55.
14. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naïve patients > 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007; 25:760-6.
15. Jackman DM, Yeap B, Lucca J, et al. Phase II trial of erlotinib in elderly patients (age > 70) with previously untreated advanced non-small cell lung cancer (NSCLC): An analysis quality of life and symptom response. J Clin Oncol 2006; 24(18 suppl):406S (Abstract 7168).
16. Gridelli C, Bareschino MA, Schettino C, et al. Erlotinib in non small cell lung cancer treatment: current status and future development. Oncologist 2007; 12:840-9.
17. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85:365-76.
18. Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ C30) for use in lung cancer clinical trials. Eur J Cancer 1994; 30A:635-42.
19. Bebchuk JD, Betensky RA. Tests for treatment group differences in the hazards for survival, before and after the occurrence of an intermediate event. Statist Med 2005; 24:359-78.
20. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38:143-51.